JP2023522331A - 血漿カリクレインの阻害剤の形態及び組成物 - Google Patents

血漿カリクレインの阻害剤の形態及び組成物 Download PDF

Info

Publication number
JP2023522331A
JP2023522331A JP2022562728A JP2022562728A JP2023522331A JP 2023522331 A JP2023522331 A JP 2023522331A JP 2022562728 A JP2022562728 A JP 2022562728A JP 2022562728 A JP2022562728 A JP 2022562728A JP 2023522331 A JP2023522331 A JP 2023522331A
Authority
JP
Japan
Prior art keywords
compound
solid form
pattern
diffraction
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522331A5 (https=
Inventor
スレシュ クマール ティッパラジュ，
ジェフリー スコット デプエ，
ヘルゲ アルフレッド ライシュ，
サミュエル アレクサンダー ストラトフォード，
ジョセフ スティーブン ハリス，
ニコラオス パパイオアヌー，
サラ ジョスリン フィンク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2023522331A publication Critical patent/JP2023522331A/ja
Publication of JP2023522331A5 publication Critical patent/JP2023522331A5/ja
Priority to JP2025122305A priority Critical patent/JP2025142238A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022562728A 2020-04-17 2021-04-16 血漿カリクレインの阻害剤の形態及び組成物 Pending JP2023522331A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025122305A JP2025142238A (ja) 2020-04-17 2025-07-22 血漿カリクレインの阻害剤の形態及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011776P 2020-04-17 2020-04-17
US63/011,776 2020-04-17
PCT/US2021/027620 WO2021211930A1 (en) 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025122305A Division JP2025142238A (ja) 2020-04-17 2025-07-22 血漿カリクレインの阻害剤の形態及び組成物

Publications (2)

Publication Number Publication Date
JP2023522331A true JP2023522331A (ja) 2023-05-30
JP2023522331A5 JP2023522331A5 (https=) 2024-04-26

Family

ID=75870731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562728A Pending JP2023522331A (ja) 2020-04-17 2021-04-16 血漿カリクレインの阻害剤の形態及び組成物
JP2025122305A Pending JP2025142238A (ja) 2020-04-17 2025-07-22 血漿カリクレインの阻害剤の形態及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025122305A Pending JP2025142238A (ja) 2020-04-17 2025-07-22 血漿カリクレインの阻害剤の形態及び組成物

Country Status (9)

Country Link
US (1) US20230167132A1 (https=)
EP (2) EP4623913A3 (https=)
JP (2) JP2023522331A (https=)
DK (1) DK4136091T3 (https=)
ES (1) ES3035604T3 (https=)
FI (1) FI4136091T3 (https=)
PL (1) PL4136091T3 (https=)
PT (1) PT4136091T (https=)
WO (1) WO2021211930A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028362A1 (en) * 2017-08-04 2019-02-07 Dyax Corp. INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518713A (ja) * 2003-01-21 2006-08-17 エス．エス．シー．アイ．インコーポレイテッド 新規な共結晶化
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
JP2014502251A (ja) * 2010-07-23 2014-01-30 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノールの塩または共結晶
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2012097333A2 (en) * 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518713A (ja) * 2003-01-21 2006-08-17 エス．エス．シー．アイ．インコーポレイテッド 新規な共結晶化
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
JP2014502251A (ja) * 2010-07-23 2014-01-30 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノールの塩または共結晶
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005769402 *
高田則幸: "Ｃｏｃｒｙｓｔａｌのスクリーニングと原薬物性改善への応用", PHARM TECH JAPAN, vol. 25, no. 12, JPN6013060384, 2009, pages 155 - 166, ISSN: 0005769403 *

Also Published As

Publication number Publication date
PL4136091T3 (pl) 2025-08-18
ES3035604T3 (en) 2025-09-05
WO2021211930A1 (en) 2021-10-21
EP4136091A1 (en) 2023-02-22
EP4136091B1 (en) 2025-05-28
FI4136091T3 (fi) 2025-07-25
EP4623913A2 (en) 2025-10-01
US20230167132A1 (en) 2023-06-01
WO2021211930A8 (en) 2021-12-16
JP2025142238A (ja) 2025-09-30
PT4136091T (pt) 2025-08-22
EP4623913A3 (en) 2025-12-24
DK4136091T3 (da) 2025-08-18

Similar Documents

Publication Publication Date Title
TW397825B (en) Aroyl-piperidine derivatives
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
KR20150065189A (ko) 인자 XIa 억제제의 결정질 형태
US12030895B2 (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
JP2025142238A (ja) 血漿カリクレインの阻害剤の形態及び組成物
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
JP2025532510A (ja) アルファ－１アンチトリプシンの調節剤
US20080171773A1 (en) FACTOR Xa INHIBITOR
KR20250159055A (ko) 아제티딘 parp1 억제제의 결정질 형태
TWI462915B (zh) 一種組織胺ｈ３受體拮抗劑的新穎富馬酸鹽
EP1397348B1 (en) Factor xa inhibitor
JPH07267954A (ja) 新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１ノナン−化合物、その製法及び抗不整脈剤
JP5796872B2 (ja) 第Ｘａ因子阻害剤の結晶性塩
US7371864B2 (en) Crystalline forms of a factor Xa inhibitor
KR102013567B1 (ko) ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 다형체
WO2021211938A1 (en) Solid forms of inhibitors of plasma kallikrein
KR102013566B1 (ko) ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 결정성 용매화물
TWI221152B (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
CN120271571A (zh) 一类谷胺酰胺环化酶抑制剂及其用途
CN121517394A (zh) 一种取代的吡啶丙酸衍生物及其用途
HK1219484B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121